Named Patient Supplies enable healthcare professionals, on behalf of their patients, to access medicines approved or nearing approval in other countries before marketing authorisation has been granted in their home country.
The treating healthcare professional makes the clinical judgment that no comparable or satisfactory alternative approved therapy is currently available for a given patient and that the probable risks from the investigational drug are not greater than the probable risks from the condition itself.
In the UK, provision for granting access to investigational drugs for patients is governed by The Medicines and Healthcare Regulatory Agency (MHRA), who are responsible for ensuring the safe supply of medicines to patients. The MHRA may provide licenses to companies who demonstrate the capabilities and facilities to manage the provision of unlicensed medicines in accordance with MHRA guidelines. In the US, the Food and Drug Administration (FDA) governs the equivalent process.
Often grouped under the labels of compassionate use, special access, expanded access, or named patient supply, these provisions allow companies to provide patients with access to their medicines while the drugs are still in the preapproval phase. Strict regulations governing such access define access criteria, data collection, non-promotion, and control of drug distribution.
Examples of circumstances where such access may be granted include:
A medicine for which no clinical alternative exists is still undergoing clinical trials;
A licensed medicine existed, but is discontinued, and an unlicensed alternative that does exist is still in development;
A product is awaiting approval in a particular country, but is licensed elsewhere in the world;
A local shortage exists for an essential medication; or
A patient has an immediate clinical need, but is not eligible for a trial, and the treating healthcare professional believes that the patient might benefit from taking the drug.
Companies such as BTG which are authorised to distribute on a named patient basis merely distribute and are not involved in the patient doctor relationship. All information regarding patients is controlled under specific privacy and data protection legislation. BTG can only distribute where permitted to do so and only in response to an unsolicited information or product supply request.
Our list of Named Patient Distributors is organised according to territory.
Please note: this contact information is intended for healthcare professionals only.
Unless otherwise noted below contact the following Named Patient Distributors:
EFFECTIVE 1ST JANUARY 2021 - WEP Clinical will be the supplier in Europe and other territories for DigiFab® in addition to Voraxaze®
DigiFab® and Voraxaze® in Europe and other territories
CroFab® (crotalidae polyvalent immune fab (ovine)) BTG International Inc.
CroFab® (crotalidae polyvalent immune fab (ovine)) is approved for sale in this territory. Please refer to our Customer Service information in the Contact Us section, accessible through links at the top and bottom of this page.
DigiFab® (digoxin immune fab (ovine)) BTG International Inc.
DigiFab® (digoxin immune fab (ovine)) is approved for sale in this territory. Please refer to our Customer Service information in the Contact Us section, accessible through links at the top and bottom of this page.
Voraxaze® (glucarpidase) BTG International Inc.
Voraxaze® (glucarpidase) is approved for sale in this territory. Please refer to our Customer Service information in the Contact Us section, accessible through links at the top and bottom of this page.
Cookies on the BTG Specialty Pharmaceuticals website